35 results
8-K
OCUL
Ocular Therapeutix Inc
3 Jun 24
Cost Associated with Exit or Disposal Activities
9:15am
% of the Company’s workforce, as part of an initiative to prioritize Company resources on the clinical development of AXPAXLI™ (axitinib intravitreal implant
424B5
kzow3 754eymc5krh6l
16 Dec 20
Prospectus supplement for primary offering
4:04pm
424B5
pungerpkns xt89xr1yv
14 Dec 20
Prospectus supplement for primary offering
5:21pm
424B5
cvdqdze pz7wpij8sf
14 Oct 20
Prospectus supplement for primary offering
4:17pm
424B5
ihggmpol
13 Oct 20
Prospectus supplement for primary offering
5:24pm
424B5
d1a 1cd47c
20 May 20
Prospectus supplement for primary offering
4:27pm
424B5
eyykxtwy y0im7zsb
19 May 20
Prospectus supplement for primary offering
4:54pm